Patents Assigned to Xencor, Inc.
  • FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20140294812
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventor: Gregory Alan Lazar
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140288275
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 25, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20140249297
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: January 27, 2014
    Publication date: September 4, 2014
    Applicant: XENCOR, INC.
    Inventors: Gregory A. LAZAR, Bassil I. DAHIYAT, Matthew J. BERNETT
  • Optimized Fc variants and methods for their generation
    Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8802820
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized Fc variants
    Patent number: 8802823
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20140212435
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory L. Moore, John Desjarlais
  • OPTIMIZED ANTIBODIES THAT TARGET HM1.24
    Publication number: 20140205605
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 24, 2014
    Applicant: XENCOR, INC.
    Inventor: XENCOR, INC.
  • Optimized Fc variants
    Patent number: 8753628
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 8753629
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFE
    Publication number: 20140161790
    Abstract: The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 12, 2014
    Applicant: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Alan Lazar
  • Optimized Fc Variants
    Patent number: 8735547
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized fc variants and methods for their generation
    Patent number: 8734791
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants having increased affinity for fcyrllc
    Patent number: 8735545
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Antibodies That Target CD19
    Publication number: 20140112916
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 24, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20140112924
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 24, 2014
    Applicant: XENCOR, INC.
    Inventors: GREGORY A. LAZAR, MATTHEW J. BERNETT
  • Optimized Antibodies That Target CD19
    Publication number: 20140086906
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: August 5, 2013
    Publication date: March 27, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • OPTIMIZED Fc VARIANTS
    Publication number: 20140073768
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • FC VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
    Publication number: 20140056879
    Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XENCOR, INC.
    Inventor: GREGORY A. LAZAR
  • Antibodies with modified isoelectric points
    Patent number: 8637641
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett